18.02.2015 Views

Financial Statements of - Shoppers Drug Mart

Financial Statements of - Shoppers Drug Mart

Financial Statements of - Shoppers Drug Mart

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

SHOPPERS DRUG MART CORPORATION<br />

Notes to the Consolidated <strong>Financial</strong> <strong>Statements</strong><br />

(unaudited)<br />

(in thousands <strong>of</strong> Canadian dollars, except per share data)<br />

4. DETERMINATION OF FAIR VALUES (continued)<br />

(f) Share-based Payment Transactions<br />

The grant date fair values <strong>of</strong> stock options granted to employees are measured using the Black-<br />

Scholes option-pricing model (the “model”). Measurement inputs to the model include share price on<br />

measurement date, exercise price <strong>of</strong> the instruments, expected volatility, weighted average expected<br />

life <strong>of</strong> the instruments (based on historical experience and general option holder behaviour), expected<br />

dividends and the risk-free interest rate (based on government bonds). The fair value <strong>of</strong> the amount<br />

payable to employees in respect <strong>of</strong> cash-settled share-based payments is measured based on the<br />

Company’s common share price.<br />

5. BUSINESS ACQUISITIONS<br />

In the normal course <strong>of</strong> business, the Company acquires the assets or shares <strong>of</strong> pharmacies. The total cost<br />

<strong>of</strong> these acquisitions during the 12 weeks ended March 26, 2011 <strong>of</strong> $6,265 (2010: $9,833) was allocated<br />

primarily to goodwill and other intangible assets based on their fair values. The goodwill acquired<br />

represents the benefits the Company expects from the acquisitions. The Company expects that $38 (2010:<br />

$6,410) <strong>of</strong> acquired goodwill will be deductible for tax purposes.<br />

The values <strong>of</strong> assets acquired and liabilities assumed have been valued at the acquisition date, generally<br />

using fair values. See Note 4 to these consolidated financial statements for the methods used in<br />

determining fair values. The intangible assets acquired are composed <strong>of</strong> prescription files. In<br />

determining the fair value <strong>of</strong> prescription files acquired, the Company applied a pre-tax discount rate <strong>of</strong> 9<br />

percent (2010: 8 percent) to the estimated expected future cash flows.<br />

The Company incurred acquisition-related costs <strong>of</strong> $5 (2010: $nil), representing primarily legal fees.<br />

These acquisition-related costs have been included in net earnings, in operating and administrative<br />

expenses for the 12 weeks ended March 26, 2011 and March 27, 2010.<br />

The operations <strong>of</strong> the acquired pharmacies have been included in the Company’s results <strong>of</strong> operations<br />

from the date <strong>of</strong> acquisition.<br />

6. COST OF GOODS SOLD<br />

During the 12 weeks ended March 26, 2011, the Company recognized $10,726 (2010: $9,656) <strong>of</strong> writedowns<br />

<strong>of</strong> inventory as a result <strong>of</strong> net realizable value being lower than cost in cost <strong>of</strong> goods sold in the<br />

consolidated statements <strong>of</strong> earnings.<br />

During the 12 weeks ended March 26, 2011 and March 27, 2010, the Company did not reverse any<br />

significant inventory write-downs recognized in previous periods.<br />

42

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!